

Appendix Table. Detailed Maternal and Infant Demographic Characteristics

Characteristics	Amphetamine-dextroamphetamine ^a		<i>P</i> Value
	No Use (n=104)	Use (n=54)	
Birth defects			
None	102 (98.1)	53 (98.1)	.99 ^b
Birth defect	1 (1.0) (hypospadias)	1 (1.9) (intestinal malrotation)	.99 ^b
Complications of pregnancy			
No complication	74 (71.2)	30 (55.6)	.07 ^c
Gestational hypertension	10 (9.6)	8 (14.8)	.31 ^c
Preeclampsia/eclampsia/HELLP syndrome	3 (2.9)	3 (5.6)	.76 ^b
PPROM	6 (5.8)	5 (9.3)	.39 ^c
Preterm labor	3 (2.9)	3 (5.6)	.39 ^b
Gestational diabetes	4 (3.8)	3 (5.6)	.60 ^b
Postpartum hemorrhage	7 (6.7)	4 (7.4)	.85 ^b
Hyperemesis gravidarum	1 (1.0)	2 (3.7)	.22 ^b
IUGR diagnosed in pregnancy	3 (2.9)	2 (3.7)	.76 ^b
Feeding methods			
Exclusively breastfeeding	75 (72.1)	33 (61.1)	.21 ^c
Formula	8 (7.7)	15 (27.8)	<.001 ^c

Both breastfeeding and formula	20 (19.2)	6 (11.1)	.21 ^c
Maternal comorbidities			
No medical comorbidities	53 (51.0)	9 (16.7)	<.001 ^c
Chronic hypertension	2 (1.9)	1 (1.9)	.99 ^b
Diabetes mellitus, type 1	2 (1.9)	1 (1.9)	.99 ^b
Chronic pain	0 (0.0)	2 (3.7)	.11 ^b
Bariatric surgery	0 (0.0)	2 (3.7)	.11 ^b
Major depression	17 (16.4)	35 (64.8)	<.001 ^c
Anxiety or panic disorder	16 (15.4)	26 (48.2)	<.001 ^c
Thyroid disease	5 (4.8)	6 (11.1)	.13 ^c
Inflammatory bowel disease	2 (1.9)	0 (0.0)	.31 ^b
Chronic kidney disease	0 (0.0)	1 (1.9)	.16 ^b
Cardiovascular disease (eg, congenital, MI)	4 (3.9)	1 (1.9)	.51 ^b
History of substance abuse	8 (7.7)	18 (33.3)	<.001 ^c
History of eating disorder	2 (1.9)	2 (3.7)	.49 ^b
Migraines	22 (21.2)	21 (38.9)	.03 ^c
Celiac disease	0 (0.0)	1 (1.9)	.16 ^b
Bipolar disorder	0 (0.0)	11 (20.4)	<.001 ^c

Infection during pregnancy			
No maternal infection during pregnancy (including HIV, HCV, HBV, HSV diagnosed in pregnancy, Zika virus, CMV, malaria, toxoplasmosis, and syphilis)	101 (97.1)	54 (100.0)	.21 ^c
Hepatitis B infection	2 (2.0)	0 (0.0)	.44 ^b
Prescriptions			
None of the medications cited below	87 (83.7)	18 (33.3)	<.001 ^c
Psychiatric medication (eg, SSRI, SNRI, antipsychotics, lithium)	10 (9.6)	32 (59.3)	<.001 ^c
Opioids	3 (2.9)	8 (14.8)	.01 ^b
Other stimulant	0 (0.0)	2 (3.7)	.11 ^b
β-Blockers	4 (3.9)	1 (1.9)	.51 ^b
Prenatal substance exposure			
No prenatal substance exposure	90 (86.5)	36 (66.7)	<.001 ^c
Smoking in pregnancy	13 (12.5)	18 (33.3)	<.001 ^c
Maternal disclosure of drug use in pregnancy	5 (4.8)	3 (5.6)	.82 ^b
Maternal drug screen positive	1 (1.0)	1 (1.9)	.62 ^b
Marijuana	6 (5.8)	4 (7.4)	.67 ^b
Methamphetamine	0 (0.0)	1 (1.9)	.16 ^b

Cocaine	0 (0.0)	1 (1.9)	.16 ^b
Alcohol consumption after first prenatal visit	1 (1.0)	0 (0.0)	.47 ^b
Symptoms of neonatal abstinence syndrome			
None	91 (87.5)	45 (83.3)	.65 ^c
Irritability	0 (0.0)	2 (3.7)	.11 ^b
Sleep/wake disturbance	0 (0.0)	1 (1.9)	.34 ^b
Hypertonicity	0 (0.0)	2 (3.7)	.11 ^b
Tremor	0 (0.0)	2 (3.7)	.11 ^b
Feeding difficulty	13 (12.5)	8 (14.8)	.90 ^c
Autonomic dysfunction	0 (0.0)	2 (3.7)	.11 ^b

Abbreviations: CMV, cytomegalovirus; HELLP, hemolysis, elevated liver enzyme levels, and low platelet count; HBV, hepatitis B virus; HCV, hepatitis C virus; HSV, herpes simplex virus; IUGR, intrauterine growth restriction; MI, myocardial infarction; PPROM, premature rupture of membranes; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

^a Values are presented as number and percentage of patients unless specified otherwise.

^b Fisher exact test.

^c χ^2 test.